Among the approved drugs in oncology are two rapamycin analogs inhibiting the mTOR complex 1 (mTORC1): (i) temsirolimus for the treatment of advanced renal cell carcinoma and (ii) everolimus for advanced renal cell carcinoma, pancreatic neuroendocrine tumors and advanced hormone receptor-positive, HER2-negative breast cancer (in combination with exemestane). The gene discussed is ERBB2; the disease is breast carcinoma.